angiotensin receptor blocker


Also found in: Dictionary, Acronyms.

angiotensin receptor blocker (ARB),

agent that binds with angiotensin receptors, thus preventing access of angiotensin II to the receptor and consequently reducing the vasoconstriction produced by this agonist; used in the treatment of hypertension.

angiotensin II receptor antagonist

Any of a family of agents (e.g., losartan and valsartan) that block the binding of angiotensin II (A-II) to their cognate cell receptors—AT1, AT2 and others. First-generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains to block the binding of A-II to AT1.

ARAs are an alternative to ACEI therapy in patients with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference of which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.

an·gi·o·ten·sin re·cep·tor block·er

(an'jē-ō-ten'sin rĕ-sep'tŏr blok'ĕr)
An agent (e.g., losartan) that binds with angiotensin receptors, thus preventing access of angiotensin II to the receptor and consequently reducing the vasoconstriction produced by this agonist; used in the treatment of hypertension.
Mentioned in ?
References in periodicals archive ?
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
ACE inhibitors and ARBs: one or the other--not both--for high-risk patients: the combination of an ACE inhibitor and an ARB reduces proteinuria, but leads to worse renal outcomes
The VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) study involved 1,448 patients with type 2 diabetes and moderate diabetic nephropathy who were treated for at least 30 days with 100 mg daily of the angiotensin receptor blocker (ARB) losartan, as is standard practice in patients with diabetes.
ACE/ARB combo raised risks in diabetic nephropathy
The measures identified for heart failure include discharge instructions, left ventricular function assessment as measured by an echocardiogram, discharge prescription for an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker for left ventricular systolic dysfunction, and smoking cessation advice/counseling.
Heart failure
Norvasc, a calcium channel blocker, relaxes blood vessels, while olmesartan uses an angiotensin receptor blocker to ease blood-vessel constriction.
Daiichi Sankyo Co's experimental blood pressure drug combining its Benicar pill with the active ingredient in Pfizer Inc's Norvasc lowered hypertension more effectively than either medicine alone, a study found
An angiotensin receptor blocker (ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor hormone Angiotensin II.
Takeda Pharmaceutical Initiates Phase II Clinical Test for Compound TAK-491 for Treatment of Hypertension
Novartis AG, Basel, Switzerland, announced the US Food and Drug Administration (FDA) has approved Diovan, the most prescribed angiotensin receptor blocker (ARB) worldwide, for a new indication to reduce cardiovascular death in patients with high risk (with left ventricular failure or left ventricular dysfunction) following a heart attack.
Novartis gets FDA approval for heart attack treatment; acquires rights to develop new dialysis treatment
The drug is Entresto[TM], a combination of the neprilysin inhibitor sacubitril and valsartan, an angiotensin receptor blocker (ARB).
Patients Report Improvement in Quality of Life with New Heart Failure Drug
The company stated that Entresto is usually administered along with other heart failure therapies in place of an ACE inhibitor or other angiotensin receptor blocker. The product is a first in class angiotensin receptor neprilysin inhibitor that decreases strain on a failing heart.
Novartis receives approval for Entresto
Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
Association between renin-angiotensin-aldosterone system blockers and postoperative atrial fibrillation in patients with mild and moderate left ventricular dysfunction/Hafif ve orta derecede sol ventrikul disfonksiyonu olan hastalarda renin-anjiyotensin-aldosteron sistem blokerleri ile kalp cerrahisi sonrasi gelisen atrial fibrilasyon arasindaki iliski
All women who were discharged on an ACE inhibitor or angiotensin receptor blocker, and lipid therapy, and 90% of those discharged on a [beta]-blocker, remained on their medications at 1-year follow-up.
Dx of metabolic syndrome often missed in women
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure.
Is combining ACE inhibitors and ARBs helpful or harmful?

Medical browser ?
Full browser ?